Related references
Note: Only part of the references are listed.A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies
A. du Bois et al.
ANNALS OF ONCOLOGY (2010)
Phase I Study of the Angiogenesis Inhibitor BIBF 1120 in Patients with Advanced Solid Tumors
Klaus Mross et al.
CLINICAL CANCER RESEARCH (2010)
Phase I Open-Label Study of Continuous Treatment with BIBF 1120, a Triple Angiokinase Inhibitor, and Pemetrexed in Pretreated Non-Small Cell Lung Cancer Patients
Peter M. Ellis et al.
CLINICAL CANCER RESEARCH (2010)
Phase I Safety, Pharmacokinetic, and Biomarker Study of BIBF 1120, an Oral Triple Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors
Isamu Okamoto et al.
MOLECULAR CANCER THERAPEUTICS (2010)
BIBF 1120: Triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy
Frank Hilberg et al.
CANCER RESEARCH (2008)
Phase II double blind study to investigate efficacy and safety of the triple angiokinase inhibitor BIBF 1120 in patients suffering from relapsed advanced non-small cell lung cancer (NSCLC)
Martin Reck et al.
JOURNAL OF THORACIC ONCOLOGY (2007)
A phase I dose escalation and pharmacokinetic study of BIBF 1120, a novel tyrosine kinase inhibitor against VEGFR, PDGFR and FGFR, in combination with docetaxel in advanced chemonaive hormone refractory prostate cancer patients (HRPC)
E. Raymond et al.
EJC SUPPLEMENTS (2007)
Metabolism and disposition of varenicline, a selective alpha 4 beta 2 acetylcholine receptor partial agonist, in vivo and in vitro
RS Obach et al.
DRUG METABOLISM AND DISPOSITION (2006)
The Orbitrap: a new mass spectrometer
QZ Hu et al.
JOURNAL OF MASS SPECTROMETRY (2005)
Angiogenesis in cancer and other diseases
P Carmeliet et al.
NATURE (2000)
Share Paper
